Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Denton

Showing results (241-250 of 484) with videos related to

Pageof 49
Sort By:
The European Respiratory Journal|January 28, 2012
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapyGregory J Keir, Toby M Maher, David M Hansell, et al.
Fibrogenesis & Tissue Repair|March 17, 2015
Erratum to: Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanismYunliang Chen, Andrew Leask, David J Abraham, et al.
Rheumatology (Oxford, England)|September 9, 2025
Impact of hand function impairment on daily life of patients with systemic sclerosis: a qualitative studyMark Greveling, Stefano Rodolfi, Nora El Bardai, et al.
Vascular Pharmacology|July 13, 2023
Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertensionJeries Abu-Hanna, Evangelos Anastasakis, Jigisha A Patel, et al.
Proteomics. Clinical Applications|August 25, 2018
Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-ßBenjamin Chaigne, Guilhem Clary, Morgane Le Gall, et al.
The Lancet. Rheumatology|January 26, 2024
Digital ulcers: should debridement be a standard of care in systemic sclerosis?Michael Hughes, Begonya Alcacer-Pitarch, Yannick Allanore, et al.
The Journal of Rheumatology|October 2, 2020
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung DiseaseDinesh Khanna, Donald P Tashkin, Athol U Wells, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 29, 2015
Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial HypertensionVincent Sobanski, Jonathan Giovannelli, Bernadette M Lynch, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 31, 2018
Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanismSumia A Bageghni, Karen E Hemmings, Ngonidzashe Zava, et al.
Rheumatology (Oxford, England)|June 9, 2023
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung diseaseYannick Allanore, Dinesh Khanna, Vanessa Smith, et al.
Pageof 49

Showing results (241-250 of 484) with videos related to

Sort By:
Pageof 49
The European Respiratory Journal|January 28, 2012
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapyGregory J Keir, Toby M Maher, David M Hansell, et al.
Fibrogenesis & Tissue Repair|March 17, 2015
Erratum to: Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanismYunliang Chen, Andrew Leask, David J Abraham, et al.
Rheumatology (Oxford, England)|September 9, 2025
Impact of hand function impairment on daily life of patients with systemic sclerosis: a qualitative studyMark Greveling, Stefano Rodolfi, Nora El Bardai, et al.
Vascular Pharmacology|July 13, 2023
Prostacyclin mimetics inhibit DRP1-mediated pro-proliferative mitochondrial fragmentation in pulmonary arterial hypertensionJeries Abu-Hanna, Evangelos Anastasakis, Jigisha A Patel, et al.
Proteomics. Clinical Applications|August 25, 2018
Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-ßBenjamin Chaigne, Guilhem Clary, Morgane Le Gall, et al.
The Lancet. Rheumatology|January 26, 2024
Digital ulcers: should debridement be a standard of care in systemic sclerosis?Michael Hughes, Begonya Alcacer-Pitarch, Yannick Allanore, et al.
The Journal of Rheumatology|October 2, 2020
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung DiseaseDinesh Khanna, Donald P Tashkin, Athol U Wells, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 29, 2015
Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial HypertensionVincent Sobanski, Jonathan Giovannelli, Bernadette M Lynch, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 31, 2018
Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanismSumia A Bageghni, Karen E Hemmings, Ngonidzashe Zava, et al.
Rheumatology (Oxford, England)|June 9, 2023
Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung diseaseYannick Allanore, Dinesh Khanna, Vanessa Smith, et al.
Pageof 49